The specter of generic rivalry has consistently loomed above copyright’s blockbuster drug, Viagra, raising questions about the outlook of Adult related drug holdings. While first periods saw impressive gains, the patent lapse has created the door for cheaper copies, likely diminishing profitability and presenting a significant danger for stakehol